Represent

Lobbying
Lobbying by The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)

Lobbying Relationship

Client

The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)

More records

Lobbying firm

The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries)

More records

S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R.4881, To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. Including issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; H.R. 5380, To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; S. 3059, the Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Issues related to Direct-to-Consumer Prescription Drug Advertisements; Issues related to Cybersecurity; Health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act 2024; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption; S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; S. 464/ H.R. 2630, the Safe Step Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; H.R. 1843/S. 1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to mental health coverage, workforce, and mental health parity; Issues related to surprise billing law and regulation; Issues related to artificial intelligence and health care issues; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; H.R. 3432/S.3651, Telemental Health Care Access Act of 2023.
Pharmacy issues related to TRICARE and the Fiscal Year 2025 National Defense Authorization Act.
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure; Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R.7535, Prescription Drug Supply Chain Pricing Transparency Act; H.R. 6986/S.3583, to address patent thickets.

Duration: January 1, 2008 to present

General Issues: Medicare/Medicaid, Health Issues, Defense, Pharmacy, Postal, Taxation/Internal Revenue Code, Trade (Domestic & Foreign), Labor Issues/Antitrust/Workplace, Immigration, Insurance, Computer Industry, Foreign Relations, Torts, Budget/Appropriations, Economics/Economic Development

Spending: about $81,794,242 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), Treasury - Dept of, Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), White House Office, Food & Drug Administration (FDA), Office of Management & Budget (OMB), Congressional Budget Office (CBO), Vice President of the U.S., State - Dept of (DOS), U.S. Trade Representative (USTR), Labor - Dept of (DOL), Executive Office of the President (EOP), Government Accountability Office (GAO), Commerce - Dept of (DOC), Health & Human Services - Dept of (HHS),, U.S. Senate,, Office of the Vice President of the United States, Executive Office of the President (EOP),, Treasury - Dept of,

Bills mentioned

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.173: Middle Class Health Benefits Tax Repeal Act of 2017

Sponsor: Mike Kelly (R-Pa.)

S.58: Middle Class Health Benefits Tax Repeal Act of 2017

Sponsor: Dean Heller (R-Nev.)

H.CON.RES.71: Establishing the congressional budget for the United States Government...

Sponsor: Diane Black (R-Tenn.)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

H.R.5659: ESRD Choice Act of 2016

Sponsor: Jason Smith (R-Mo.)

H.R.2050: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Joe Courtney (D-Conn.)

H.R.879: Ax the Tax on Middle Class Americans' Health Plans Act

Sponsor: Frank Guinta (R-N.H.)

S.2045: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Dean Heller (R-Nev.)

S.2075: American Worker Health Care Tax Relief Act of 2015

Sponsor: Sherrod Brown (D-Ohio)

S.1945: Mental Health Reform Act of 2015

Sponsor: Bill Cassidy (R-La.)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

S.2680: Mental Health Reform Act of 2016

Sponsor: Lamar Alexander (R-Tenn.)

H.R.5046: Comprehensive Opioid Abuse Reduction Act of 2016

Sponsor: F. James Sensenbrenner (R-Wis.)

H.R.2646: Helping Families in Mental Health Crisis Act of 2016

Sponsor: Tim Murphy (R-Pa.)

S.3060: Small Business Health Care Relief Act of 2016

Sponsor: Charles E. Grassley (R-Iowa)

H.R.4832: Health Savings Protection Act

Sponsor: Charles Boustany Jr. (R-La.)

H.R.2579: Securing Care for Seniors Act of 2015

Sponsor: Diane Black (R-Tenn.)

H.R.4469: Health Savings Act of 2016

Sponsor: Erik Paulsen (R-Minn.)

S.2499: Health Savings Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

S.2104: Preserving Medicare Advantage for all Medicare Beneficiaries Act of 2015

Sponsor: Rob Portman (R-Ohio)

H.R.2570: Strengthening Medicare Advantage through Innovation and Transparency for...

Sponsor: Diane Black (R-Tenn.)

H.R.2582: Seniors' Health Care Plan Protection Act of 2015

Sponsor: Vern Buchanan (R-Fla.)

H.R.1600: Patients' Access to Treatments Act of 2015

Sponsor: David McKinley (R-W.Va.)

H.R.2298: Medicare Patient Safety and Drug Abuse Prevention Act

Sponsor: Gus Bilirakis (R-Fla.)

H.R.928: To repeal the annual fee on health insurance providers enacted by the...

Sponsor: Charles Boustany Jr. (R-La.)

S.183: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

H.R.83: CAMPER Act

Sponsor: Sheila Jackson Lee (D-Texas)

H.R.1624: Protecting Affordable Coverage for Employees Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.3462: Sport Fish Restoration and Recreational Boating Safety Act of 2015

Sponsor: Garret Graves (R-La.)

S.775: Self-Insurance Protection Act

Sponsor: Bill Cassidy (R-La.)

H.R.793: Ensuring Seniors Access to Local Pharmacies Act of 2015

Sponsor: Morgan Griffith (R-Va.)

H.R.244: MAC Transparency Act

Sponsor: Doug Collins (R-Ga.)

S.754: To improve cybersecurity in the United States through enhanced sharing...

Sponsor: Richard M. Burr (R-N.C.)

H.R.3392: Carbon Capture Research and Development Act

Sponsor: Scott Peters (D-Calif.)

H.R.2753: Fairness in Firearm Testing Act

Sponsor: Jody Hice (R-Ga.)

S.210: Military Spouse Job Continuity Act of 2015

Sponsor: Bob Casey (D-Pa.)

H.R.3392: Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013

Sponsor: Gus Bilirakis (R-Fla.)

H.R.763: To repeal the annual fee on health insurance providers enacted by the...

Sponsor: Charles Boustany Jr. (R-La.)

S.603: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

H.R.3367: To amend section 9010 of the Patient Protection and Affordable Care Act...

Sponsor: Charles Boustany Jr. (R-La.)

H.R.4414: Expatriate Health Coverage Clarification Act of 2014

Sponsor: John Carney (D-Del.)

H.R.83: Consolidated and Further Continuing Appropriations Act, 2015

Sponsor: Donna M.C. Christensen (D-Virgin Islands)

H.R.3462: Self-Insurance Protection Act

Sponsor: Bill Cassidy (R-La.)

S.1735: Self-Insurance Protection Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.460: Patients' Access to Treatments Act of 2013

Sponsor: David McKinley (R-W.Va.)

S.867: Medicare Prescription Drug Program Integrity and Transparency Act of 2013

Sponsor: Mark Pryor (D-Ark.)

H.R.4577: Ensuring Seniors Access to Local Pharmacies Act of 2014

Sponsor: Morgan Griffith (R-Va.)

H.R.4115: Open Access to Courts Act of 2009

Sponsor: Jerrold Nadler (D-N.Y.)

H.R.1321: Healthy Americans Act

Sponsor: Anna G. Eshoo (D-Calif.)

S.1753: Disabled Veteran Caregiver Housing Assistance Act of 2009

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3717: Kelsey Smith Act

Sponsor: Todd Tiahrt (R-Kan.)

S.803: Healthy Workforce Act of 2009

Sponsor: Tom Harkin (D-Iowa)

S.1099: Patients' Choice Act

Sponsor: Tom Coburn (R-Okla.)

H.R.2520: Patients' Choice Act

Sponsor: Paul D. Ryan (R-Wis.)

S.1679: Affordable Health Choices Act

Sponsor: Tom Harkin (D-Iowa)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

H.R.1897: Healthy Workforce Act of 2009

Sponsor: Earl Blumenauer (D-Ore.)

S.391: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

H.CON.RES.85: Setting forth the congressional budget for the United States Government...

Sponsor: John M. Spratt Jr. (D-S.C.)

S.CON.RES.13: An original concurrent resolution setting forth the congressional budget...

Sponsor: Kent Conrad (D-N.D.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.598: To provide for a portion of the economic recovery package relating to...

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.2: Children's Health Insurance Program Reauthorization Act of 2009

Sponsor: Frank Pallone (D-N.J.)

H.R.1367: Paul Wellstone Mental Health and Addiction Equity Act of 2007

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.1424: A bill to provide authority for the Federal Government to purchase and...

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.2406: Healthcare Information Technology Enterprise Integration Act

Sponsor: Bart Gordon (D-Tenn.)

H.R.758: Breast Cancer Patient Protection Act of 2008

Sponsor: Rosa DeLauro (D-Conn.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

S.1224: Children's Health Insurance Program (CHIP) Reauthorization Act of 2007

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.1408: Health Information Technology Act of 2007

Sponsor: Debbie Stabenow (D-Mich.)

S.1455: National Health Information Technology and Privacy Advancement Act of 2007

Sponsor: Sheldon Whitehouse (D-R.I.)

S.334: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

H.R.3163: Healthy Americans Act

Sponsor: Brian Baird (D-Wash.)

H.R.6444: Healthy Americans Act

Sponsor: Debbie Wasserman Schultz (D-Fla.)

S.495: Personal Data Privacy and Security Act of 2007

Sponsor: Patrick J. Leahy (D-Vt.)

S.628: Critical Access to Health Information Technology Act of 2007

Sponsor: Norm Coleman (R-Minn.)

H.R.7129: Several Approaches to Reduce the Uninsured Act of 2008

Sponsor: Robert E. Andrews (D-N.J.)

S.558: Mental Health Parity Act of 2007

Sponsor: Pete V. Domenici (R-N.M.)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.1505: Affordable Biologics for Consumers Act

Sponsor: Judd Gregg (R-N.H.)

H.R.2761: Terrorism Risk Insurance Program Reauthorization Act of 2007

Sponsor: Michael E. Capuano (D-Mass.)

H.R.4460: Health Care Choice Act of 2007

Sponsor: John Shadegg (R-Ariz.)

S.40: National Insurance Act of 2007

Sponsor: John E. Sununu (R-N.H.)

S.2477: Health Care Choice Act of 2007

Sponsor: Jim DeMint (R-S.C.)

H.R.506: Health Partnership Through Creative Federalism Act

Sponsor: Tammy Baldwin (D-Wis.)

H.R.914: Tax Equity and Affordability Act of 2007

Sponsor: Paul D. Ryan (R-Wis.)

H.R.3234: HSA Improvement and Expansion Act of 2007

Sponsor: Eric Cantor (R-Va.)

S.397: Tax Equity and Affordability Act of 2007

Sponsor: Mel Martinez (R-Fla.)

H.R.3997: Defenders of Freedom Tax Relief Act of 2007

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.6382: Pension Protection Technical Corrections Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.1974: Pension Protection Technical Corrections Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.7327: Worker, Retiree, and Employer Recovery Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.358: Genetic Information Nondiscrimination Act of 2007

Sponsor: Olympia J. Snowe (R-Maine)

H.R.493: Genetic Information Nondiscrimination Act of 2008

Sponsor: Louise M. Slaughter (D-N.Y.)

S.1022: A bill to amend title XXI of the Social Security Act to eliminate the...

Sponsor: Saxby Chambliss (R-Ga.)

S.1023: A bill to amend title XXI of the Social Security Act to eliminate the...

Sponsor: Robert Menendez (D-N.J.)

H.R.1368: Personalized Health Information Act of 2007

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.1329: Guaranteed Access for SCHIP's Target Population Act of 2007

Sponsor: Joe L. Barton (R-Texas)

H.R.976: Children's Health Insurance Program Reauthorization Act of 2007

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.3162: Children's Health and Medicare Protection Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.2764: Consolidated Appropriations Act, 2008

Sponsor: Nita M. Lowey (D-N.Y.)

S.1893: Children's Health Insurance Program Reauthorization Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.241: Small Business Health Fairness Act of 2007

Sponsor: Sam Johnson (R-Texas)

H.R.6357: PRO(TECH)T Act of 2008

Sponsor: John D. Dingell (D-Mich.)

H.R.3545: Overdose Prevention and Patient Safety Act

Sponsor: Tim Murphy (R-Pa.)

S.1850: Protecting Jessica Grubb's Legacy Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.4616: Employer Relief Act of 2018

Sponsor: Devin Nunes (R-Calif.)

H.R.4620: Protecting Families and Small Businesses Act of 2017

Sponsor: Kristi Noem (R-S.D.)

H.R.1625: Consolidated Appropriations Act, 2018

Sponsor: Edward Royce (R-Calif.)

H.R.195: Making further continuing appropriations for the fiscal year ending...

Sponsor: Steve Russell (R-Okla.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

H.R.5795: Overdose Prevention and Patient Safety Act

Sponsor: Earl Blumenauer (D-Ore.)

H.R.6082: Overdose Prevention and Patient Safety Act

Sponsor: Markwayne Mullin (R-Okla.)

H.R.5963: To delay the reimposition of the annual fee on health insurance...

Sponsor: Kristi Noem (R-S.D.)

S.2680: Opioid Crisis Response Act of 2018

Sponsor: Lamar Alexander (R-Tenn.)

H.R.88: Shiloh National Military Park Boundary Adjustment and Parker's...

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.1034: Phair Pricing Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.640: Phair Pricing Act of 2019

Sponsor: John Kennedy (R-La.)

H.R.803: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Peter Welch (D-Vt.)

H.R.1035: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.657: A bill to amend title XXVII of the Public Health Service Act to...

Sponsor: Mike Braun (R-Ind.)

H.R.861: End Surprise Billing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

S.684: Middle Class Health Benefits Tax Repeal Act of 2019

Sponsor: Martin Heinrich (D-N.M.)

S.172: Health Insurance Tax Relief Act of 2019

Sponsor: Cory Gardner (R-Colo.)

H.R.1398: Health Insurance Tax Relief Act of 2019

Sponsor: Ami Bera (D-Calif.)

S.80: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

S.340: CREATES Act of 2019

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019

Sponsor: Bobby L. Rush (D-Ill.)

S.64: Preserve Access to Affordable Generics and Biosimilars Act

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1185: FAMILY Act

Sponsor: Rosa DeLauro (D-Conn.)

S.463: FAMILY Act

Sponsor: Kirsten E. Gillibrand (D-N.Y.)

H.R.2115: Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Sponsor: Abigail Spanberger (D-Va.)

H.R.2113: Prescription Drug STAR Act

Sponsor: Richard E. Neal (D-Mass.)

H.R.2062: Overdose Prevention and Patient Safety Act

Sponsor: Earl Blumenauer (D-Ore.)

S.1012: Protecting Jessica Grubb’s Legacy Act

Sponsor: Joe Manchin III (D-W.Va.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.2279: Safe Step Act

Sponsor: Raul Ruiz (D-Calif.)

S.1384: Prescription Drug Rebate Reform Act of 2019

Sponsor: Mitt Romney (R-Utah)

S.1215: National Defense Authorization Act for Fiscal Year 2020

Sponsor: James M. Inhofe (R-Okla.)

H.R.2500: National Defense Authorization Act for Fiscal Year 2020

Sponsor: Adam Smith (D-Wash.)

H.R.2996: Labor, Human, and Civil Rights Trade Policy Act

Sponsor: John Lewis (D-Ga.)

H.R.3502: Protecting People From Surprise Medical Bills Act

Sponsor: Raul Ruiz (D-Calif.)

H.R.2328: Reauthorizing and Extending America’s Community Health Act

Sponsor: Tom O'Halleran (D-Ariz.)

H.R.3630: No Surprises Act

Sponsor: Frank Pallone (D-N.J.)

S.1323: Utilizing National Data, Effectively Reforming Standards and Tools, to...

Sponsor: Rob Portman (R-Ohio)

S.2546: Safe Step Act

Sponsor: Lisa Murkowski (R-Alaska)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.2296: More Efficient Tools to Realize Information for Consumers Act

Sponsor: Jan Schakowsky (D-Ill.)

H.R.4946: Ensuring Seniors Access to Local Pharmacies Act of 2019

Sponsor: Peter Welch (D-Vt.)

H.R.5281: Drug Price Transparency in Medicaid Act of 2019

Sponsor: Buddy Carter (R-Ga.)

H.R.5304: PBM Transparency in Prescription Drug Costs Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.6379: Workforce Emergency Response Act of 2020

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.5800: Ban Surprise Billing Act

Sponsor: Robert C. Scott (D-Va.)

H.R.6644: To require group health plans and health insurance issuers offering...

Sponsor: Kim Schrier (D-Wash.)

S.3741: Health Care at Home Act of 2020

Sponsor: Tina Smith (D-Minn.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.6810: Health Care Protection Act

Sponsor: Rodney Davis (R-Ill.)

H.R.6514: Worker Health Coverage Protection Act

Sponsor: Robert C. Scott (D-Va.)

H.R.6395: William M. (Mac) Thornberry National Defense Authorization Act for...

Sponsor: Adam Smith (D-Wash.)

S.4049: National Defense Authorization Act for Fiscal Year 2021

Sponsor: James M. Inhofe (R-Okla.)

H.R.7659: Ensuring Parity in MA for Audio-Only Telehealth Act of 2020

Sponsor: Terri Sewell (D-Ala.)

H.R.925: The Heroes Act

Sponsor: Mike Thompson (D-Calif.)

S.4329: Continuous Health Coverage for Workers Act

Sponsor: Martha McSally (R-Ariz.)

H.R.6561: Improving Social Determinants of Health Act of 2020

Sponsor: Nanette Barragán (D-Calif.)

S.4440: Improving Social Determinants of Health Act of 2020

Sponsor: Tina Smith (D-Minn.)

S.4317: SAFE TO WORK Act

Sponsor: John Cornyn (R-Texas)

S.4318: American Workers, Families, and Employers Assistance Act

Sponsor: Charles E. Grassley (R-Iowa)

S.4321: Continuing Small Business Recovery and Paycheck Protection Program Act

Sponsor: Marco Rubio (R-Fla.)

S.4322: Safely Back to School and Back to Work Act

Sponsor: Lamar Alexander (R-Tenn.)

S.4323: TRUST Act of 2020

Sponsor: Mitt Romney (R-Utah)

H.R.7839: Continuing Access to In-Home IVIG Act

Sponsor: Doris Matsui (D-Calif.)

H.R.8308: Telehealth Coverage and Payment Parity Act

Sponsor: Dean Phillips (D-Minn.)

S.4840: Ensuring Parity in MA for Audio-Only Telehealth Act of 2020

Sponsor: Pat Roberts (R-Kan.)

H.R.3107: Improving Seniors' Timely Access to Care Act of 2019

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

H.R.4004: Social Determinants Accelerator Act of 2019

Sponsor: Cheri Bustos (D-Ill.)

S.2986: Social Determinants Accelerator Act of 2019

Sponsor: Todd Young (R-Ind.)

H.R.2166: Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021

Sponsor: Terri Sewell (D-Ala.)

S.150: Ensuring Parity in MA for Audio-Only Telehealth Act of 2021

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.1868: To prevent across-the-board direct spending cuts, and for other purposes.

Sponsor: John Yarmuth (D-Ky.)

S.748: Medicare Sequester Relief Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.1319: American Rescue Plan Act of 2021

Sponsor: John Yarmuth (D-Ky.)

S.263: Worker Health Coverage Protection Act

Sponsor: Richard J. Durbin (D-Ill.)

H.R.379: Improving Social Determinants of Health Act of 2021

Sponsor: Nanette Barragán (D-Calif.)

S.104: Improving Social Determinants of Health Act of 2021

Sponsor: Tina Smith (D-Minn.)

H.R.2608: Ensuring Seniors Access to Local Pharmacies Act of 2021

Sponsor: Peter Welch (D-Vt.)

H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021

Sponsor: David McKinley (R-W.Va.)

H.R.3554: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Peter Welch (D-Vt.)

S.1909: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Jon Tester (D-Mont.)

H.R.4074: Addressing Social Determinants in Medicare Advantage Act of 2021

Sponsor: Gus Bilirakis (R-Fla.)

H.R.3173: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.909: Prescription Drug Price Relief Act of 2021

Sponsor: Bernard Sanders (ID-Vt.)

S.908: Medicare Drug Price Negotiation Act

Sponsor: Bernard Sanders (ID-Vt.)

S.920: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.1332: Telehealth Modernization Act

Sponsor: Buddy Carter (R-Ga.)

S.368: Telehealth Modernization Act

Sponsor: Tim Scott (R-S.C.)

S.1512: CONNECT for Health Act of 2021

Sponsor: Brian Schatz (D-Hawaii)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2164: Lower Costs, More Cures Act of 2021

Sponsor: Michael D. Crapo (R-Idaho)

H.R.4350: National Defense Authorization Act for Fiscal Year 2022

Sponsor: Adam Smith (D-Wash.)

S.CON.RES.14: A concurrent resolution setting forth the congressional budget for the...

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

S.1720: Postal Service Reform Act of 2021

Sponsor: Gary Peters (D-Mich.)

H.R.3076: Postal Service Reform Act of 2022

Sponsor: Carolyn B. Maloney (D-N.Y.)

S.610: Protecting Medicare and American Farmers from Sequester Cuts Act

Sponsor: Tim Kaine (D-Va.)

S.3018: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Roger Marshall (R-Kan.)

S.499: Improving Health Insurance Affordability Act of 2021

Sponsor: Jeanne Shaheen (D-N.H.)

S.1605: National Defense Authorization Act for Fiscal Year 2022

Sponsor: Rick Scott (R-Fla.)

S.3593: Telehealth Extension and Evaluation Act

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Sponsor: Angie Craig (D-Minn.)

S.3700: Affordable Insulin Now Act

Sponsor: Raphael Warnock (D-Ga.)

H.R.7666: Restoring Hope for Mental Health and Well-Being Act of 2022

Sponsor: Frank Pallone (D-N.J.)

H.R.7780: Mental Health Matters Act

Sponsor: Mark DeSaulnier (D-Calif.)

S.4293: Pharmacy Benefit Manager Transparency Act of 2022

Sponsor: Maria Cantwell (D-Wash.)

S.1388: Prescription Pricing for the People Act of 2021

Sponsor: Charles E. Grassley (R-Iowa)

H.R.7900: National Defense Authorization Act for Fiscal Year 2023

Sponsor: Adam Smith (D-Wash.)

H.R.7776: James M. Inhofe National Defense Authorization Act for Fiscal Year 2023

Sponsor: Peter A. DeFazio (D-Ore.)

S.113: Prescription Pricing for the People Act of 2023

Sponsor: Charles E. Grassley (R-Iowa)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

S.1001: Telehealth Expansion Act of 2023

Sponsor: Steve Daines (R-Mont.)

S.1967: PBM Act

Sponsor: Robert Menendez (D-N.J.)

H.R.3282: Promoting Transparency and Healthy Competition in Medicare Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.3284: Providers and Payers COMPETE Act

Sponsor: Michael C. Burgess (R-Texas)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

S.1542: DRUG Act

Sponsor: Roger Marshall (R-Kan.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

H.R.2666: MVP Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.3561: PATIENT Act of 2023

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.269: To authorize an additional district judgeship for the district of Idaho.

Sponsor: Mike Simpson (R-Idaho)

H.R.3281: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.3285: Fairness for Patient Medications Act

Sponsor: Morgan Griffith (R-Va.)

H.R.3262: To amend title XI of the Social Security Act to increase transparency of...

Sponsor: Jan Schakowsky (D-Ill.)

H.R.3290: To amend title III of the Public Health Service Act to ensure...

Sponsor: Larry Bucshon (R-Ind.)

H.R.2813: Self-Insurance Protection Act

Sponsor: Robert Good (R-Va.)

S.727: Insulin for All Act of 2023

Sponsor: Bernard Sanders (ID-Vt.)

S.1269: INSULIN Act of 2023

Sponsor: Jeanne Shaheen (D-N.H.)

S.146: Cap Insulin Prices Act

Sponsor: Joshua Hawley (R-Mo.)

S.954: Affordable Insulin Now Act of 2023

Sponsor: Raphael Warnock (D-Ga.)

H.R.1488: Affordable Insulin Now Act

Sponsor: Angie Craig (D-Minn.)

H.R.1587: Making Insulin Affordable for All Children Act

Sponsor: Greg Landsman (D-Ohio)

H.R.1485: Insulin for All Act of 2023

Sponsor: Cori Bush (D-Mo.)

H.R.824: Telehealth Benefit Expansion for Workers Act of 2023

Sponsor: Tim Walberg (R-Mich.)

H.R.1843: Telehealth Expansion Act of 2023

Sponsor: Michelle Steel (R-Calif.)

H.R.3799: CHOICE Arrangement Act

Sponsor: Kevin Hern (R-Okla.)

S.464: No Tax Subsidies for E-Cigarette and Tobacco Ads Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.2630: Safe Step Act

Sponsor: Brad Wenstrup (R-Ohio)

H.R.5376: Share the Savings with Seniors Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

H.R.5385: Medicare PBM Accountability Act

Sponsor: Greg Landsman (D-Ohio)

H.R.4881: To amend title XVIII of the Social Security Act to limit cost sharing...

Sponsor: Nicole Malliotakis (R-N.Y.)

S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act

Sponsor: James Lankford (R-Okla.)

H.R.5688: Bipartisan HSA Improvement Act of 2023

Sponsor: Lloyd Smucker (R-Pa.)

H.R.5687: HSA Modernization Act of 2023

Sponsor: Beth Van Duyne (R-Texas)

S.2840: Bipartisan Primary Care and Health Workforce Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.2670: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Mike D. Rogers (R-Ala.)

S.2226: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Jack Reed (D-R.I.)

H.R.2691: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2436: NO PBMs Act

Sponsor: Joe Manchin III (D-W.Va.)

S.2405: Strengthening Pharmacy Access for Seniors Act

Sponsor: John Thune (R-S.D.)

S.2254: Medicare PBM Accountability Act

Sponsor: Catherine Cortez Masto (D-Nev.)

S.2052: Protect Patient Access to Pharmacies Act

Sponsor: Jon Tester (D-Mont.)

H.R.4822: Health Care Price Transparency Act of 2023

Sponsor: Jason Smith (R-Mo.)

H.R.4508: Hidden Fee Disclosure Act of 2023

Sponsor: Joe Courtney (D-Conn.)

H.R.4507: Transparency in Coverage Act of 2023

Sponsor: Robert Good (R-Va.)

H.R.4895: Lowering Drug Costs for American Families Act

Sponsor: Frank Pallone (D-N.J.)

H.R.5378: Lower Costs, More Transparency Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.4527: Health DATA Act of 2023

Sponsor: Lori Chavez-DeRemer (R-Ore.)

S.2973: Modernizing and Ensuring PBM Accountability Act

Sponsor: Ron Wyden (D-Ore.)

H.R.3008: Drug Shortage Prevention Act of 2023

Sponsor: Sara Jacobs (D-Calif.)

H.R.3810: Drug Origin Transparency Act of 2023

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.3793: Ensuring Access to Lifesaving Drugs Act of 2023

Sponsor: Elissa Slotkin (D-Mich.)

H.R.167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023

Sponsor: Morgan Griffith (R-Va.)

H.R.5380: To amend title XVIII of the Social Security Act to increase data...

Sponsor: John Sarbanes (D-Md.)

H.R.5393: To amend title XVIII of the Social Security Act to ensure fair...

Sponsor: Morgan Griffith (R-Va.)

H.R.5372: Expanding Seniors' Access to Lower Cost Medicines Act of 2023

Sponsor: John Joyce (R-Pa.)

H.R.1352: Increasing Access to Biosimilars Act of 2023

Sponsor: Richard Hudson (R-N.C.)

H.R.5386: Cutting Copays Act

Sponsor: Morgan McGarvey (D-Ky.)

S.3059: REAL Health Providers Act

Sponsor: Michael Bennet (D-Colo.)

S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Sponsor: Ron Wyden (D-Ore.)

S.3393: SUPPORT for Patients and Communities Reauthorization Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.6283: DRUG Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.2406: PBM Oversight Act of 2023

Sponsor: Thomas R. Carper (D-Del.)

S.3548: Health Care Prices Revealed and Information to Consumers Explained...

Sponsor: Mike Braun (R-Ind.)

H.R.4189: CONNECT for Health Act of 2023

Sponsor: Mike Thompson (D-Calif.)

S.2016: CONNECT for Health Act of 2023

Sponsor: Brian Schatz (D-Hawaii)

H.R.3432: Telemental Health Care Access Act of 2023

Sponsor: Doris Matsui (D-Calif.)

S.3651: Telemental Health Care Access Act of 2024

Sponsor: Bill Cassidy (R-La.)

H.R.7535: Prescription Drug Supply Chain Pricing Transparency Act

Sponsor: Yadira Caraveo (D-Colo.)

H.R.6986: To address patent thickets.

Sponsor: Jodey Arrington (R-Texas)

S.3583: A bill to address patent thickets.

Sponsor: Peter Welch (D-Vt.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
G. William Hoagland	Sr. Advisor Vice President, Federal Affairs Vice President, Public Policy
Kristin Julason Damato	Vice President, Federal Government Affairs Vice President, Federal Affairs Vice President, Public Policy Vice Presidetn, Federal Affairs
Dolly Judge	Vice President, Federal Government Affairs Vice President, Federal Affairs
Brendan Devine	Staff Director, Rep. Diana DeGette
David Schwartz	Chief Health Counsel, Senate Finance Committee
JILL CANINO	Professional Staff, Committee on Aging
Kristin Julason D'Amato	Vice President, Public Policy
Krisitn Julason Damato	Vice President, Federal Affairs
Courtney Lawrence	Legislative Director, U.S. Representative Bill Cassidy; Legislative Correspondent and Staff Assistant, U.S. Representative Tom Price
Gary Kline	Senior Policy Advisor, Congressman Brian Bilbray (R-CA)
Emily Katz	Legislative Aide,U.S. Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer Legislative Aide, U.S.Senator Ron Wyden Legislative Assistant,U.S. Senator Ron Wyden Health Policy Director,U.S. Representative Diana DeGette Health Policy Advisor,U.S. Senator Barbara Boxer Senior Health Policy Advisor,U.S. Senator Barbara Boxer
Chris Davis	Legislative Director and Senior Policy Advisor, Rep. Rick Boucher (D-VA) Intern, Rep. David Price (D-NC)
Joe Dunn	Chief of Staff, Rep. Jahana Hayes; Legislative Director and Senior Policy Advisor, Sen. Chris Murphy; Legislative Director, Senior Policy Advisor and Legislative Assistant, Rep. Anthony Weiner
Jaymi Light	Staff Assistant, Rep. Todd Young; Legislative Correspondent/Press Assistant, Rep. Todd Young; Legislative Assistant, Rep. Todd Young; Legislative Assistant, U.S. Senator Todd Young; Health Policy Director, U.S. Senator Todd Young
Chris Hartmann	1)Chief of Staff, Congressman Rush Holt (NJ-12) 2)Legislative Director, Congressman Rush Holt (NJ-12) 3)Legislative Assistant, Congressman Rush Holt (NJ-12) 4)Legislative Assistant, Congressman Bart Stupak (MI-1)
Julien Mitchell Relfe	1)Legislative Director and Counsel, Rep. Bradley Byrne (AL-01) 2)Legislative Counsel, Rep. Bradley Byrne (AL-01) 3)Floor Monitor, Senate Republican Conference 4)Legislative Correspondent/Staff Assistant/Scheduler, Rep. Spencer Bachus (AL-06)
Amy Zettle	n/a
Karen Lynn Nonnemaker	n/a
Jill Kaleta	n/a
Richad Merski	n/a
Richard Merski	n/a
Karen Nonnenmaker	n/a
Nonnemaker Karen Lynn	n/a
Karen Nonnemaker	n/a
G.William Hoagland	n/a
Jill Canino Kaleta	n/a
Kathryn Gallagher	n/a
Sergio Santiviago	n/a
Lisa Le Gette	n/a
Rich Merski	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries) had in-house lobbyists. The report was filed on April 22. Original Filing: 301574570.xml

Lobbying Issues

S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R.4881, To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. Including issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; H.R. 5380, To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; S. 3059, the Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to Direct-to-Consumer Prescription Drug Advertisements; Issues related to Cybersecurity; Health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act 2024; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption; S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; S. 464/ H.R. 2630, the Safe Step Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; H.R. 1843/S. 1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to mental health coverage, workforce, and mental health parity; Issues related to surprise billing law and regulation; Issues related to artificial intelligence and health care issues; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; H.R. 3432/S.3651, Telemental Health Care Access Act of 2023.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure; Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R.7535, Prescription Drug Supply Chain Pricing Transparency Act; H.R. 6986/S.3583, to address patent thickets.

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries) had in-house lobbyists. The report was filed on Jan. 22. Original Filing: 301539792.xml

Lobbying Issues

Issues related to the Improving Seniors Timely Access to Care Act of 2021; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule; Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications; S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes; Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R.4881, To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. Including issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; H.R. 5380, To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage; H.R. 5393, the Transparency and Fairness for Pharmacies Act (Reps. Griffith and Carter); H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; S. 3059, The Requiring Enhanced & Accurate Lists of (REAL) Health Providers Act; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act).

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to surprise billing law and regulation; Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; Issues related to removing barriers to biosimilar medicine access; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program; Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S 954, Affordable Insulin Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for all Act of 2023; Issues related to mental health coverage, workforce, and mental health parity. S. 5093, Behavioral Health Network and Directory Improvement Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; Issues relating to S. 464/ H.R. 2630, the Safe Step Act; related amendment to S. 1339, the Pharmacy Benefit Manager Reform Act; H.R. 5688, the Bipartisan HSA Improvement Act of 2023; H.R. 5687, the HSA Modernization Act of 2023; S. 2840, Bipartisan Primary Care and Health Workforce Act and issues related commercial insurance, telehealth, and pharmacy benefits; H.R. 1843/S. 1001, the Telehealth Expansion Act of 2023 and related issues; S. 3393 Support for Patients and Communities Reauthorization Act; Issues related to artificial intelligence and health care issues; Issues related to P.L. 93-406, Employee Retirement Income Security Act of 1974 (ERISA), preemption.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; S. 2052, Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R. 3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries) had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301515590.xml

Lobbying Issues

Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries) had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301491112.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues related to surprise billing law and regulation. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to removing barriers to biosimilar medicine access. Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program. Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, the PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. H.R. 2813, Self-Insurance Protection Act. Issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146, Cap Insulin Prices Act; S. 954, Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; H.R. 1485, Insulin for all Act of 2023. Issues related to mental health coverage, workforce, and mental health parity. Behavioral Health Network and Directory Improvement Act. S. 1001, Issues related to the Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023; H.R. 1843, the Telehealth Expansion Act of 2023. H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues relating to H.R. 3799, Custom Health Option and Individual Care Expense Arrangement Act (the CHOICE Arrangement Act). Issues relating to S. 464 / H.R. 2630, the Safe Step Act; related amendment to S. 1339.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, The Cigna Group and subsidiaries (Formerly Cigna Corporation and subsidiaries) had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301465983.xml

Lobbying Issues

* Issues related to the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications.

Agencies Lobbied

Type of Issue

Lobbying Issues

* Issues related to surprise billing law and regulation. * Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations. * Issues related to P.L. 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. * Issues related to S. 113, the Prescription Pricing for the People Act, and S. 127, the Pharmacy Benefit Manager Transparency Act. * Issues related to removing barriers to biosimilar medicine access. * Issues related to insulin pricing. * Issues related to mental health coverage, workforce, and mental health parity. * Issues related to Quality-Adjusted Life Year (QALY) or similar metrics in health coverage legislation. * S. 1001, Issues related to the Telehealth Expansion Act. * Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Childrens Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Cigna Corporation and subsidiaries (Formerly Cigna Corporation) had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301441964.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. Issues related to P.L. 117-328, the Consolidated Appropriations Act 2023, including Pharmacy Benefit Mangers (PBM) transparency, telehealth, mental health, and health care affordability. Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. Issues related to H.R. 7780, the Mental Health Matters Act. Issues related to mental health parity in H.R. 5376 Build Back Better Act. Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. P.L. 117-103, the Consolidated Appropriations Act, 2022. P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign. Issues related to expanding availability of Association Health Plans (AHPs). Issues related to removing barriers to biosimilar medicine access.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Cigna Corporation and subsidiaries (Formerly Cigna Corporation) had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301418280.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Cigna Corporation and subsidiaries (Formerly Cigna Corporation) had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301394749.xml

Lobbying Issues

* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.

Agencies Lobbied

Type of Issue

Lobbying Issues

* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Cigna Corporation and subsidiaries (Formerly Cigna Corporation) had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301370799.xml

Lobbying Issues

* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Cigna Corporation and subsidiaries (Formerly Cigna Corporation) had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301338341.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301313010.xml

Lobbying Issues

* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact Medicare vision, dental, and hearing benefits. * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. Con Res 14 and the impact on the expansion of Medicare benefits.

Agencies Lobbied

Type of Issue

Lobbying Issues

* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301289783.xml

Lobbying Issues

* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021. * H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R.3173, the Improving Seniors Timely Access to Care Act of 2021 * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices.

Agencies Lobbied

Type of Issue

Lobbying Issues

* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301265928.xml

Lobbying Issues

* H.R 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. * H.R.1868 - To prevent across-the-board direct spending cuts, and for other purposes; issues related to preventing sequestration funding cuts to safety net programs, including Medicare. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR). * Policies that impact public programs payments for high cost drugs including gene therapies. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 748 Medicare Sequester Relief Act - to prevent substantial payment cuts to Medicare payments to health care providers from taking effect during the COVID-19 public health emergency.

Agencies Lobbied

Type of Issue

Lobbying Issues

* Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to S.263, the Worker Health Coverage Protection Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 21, 2021. Original Filing: 301245367.xml

Lobbying Issues

-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Policies that impact public programs payments for high cost drugs including gene therapies. -H.R.7659/S. 4840, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. -Issues related to prior authorization and utilization management, H.R. 3107, the Improving Seniors' Timely Access to Care Act of 2019. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -Issues related to H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020 and H.R. 4004/ S. 2986, the Social Determinants Accelerator Act of 2019. -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301222247.xml

Lobbying Issues

-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Policies that impact public programs payments for high cost drugs including gene therapies. -H.R.7659, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.

Agencies Lobbied

Type of Issue

Lobbying Issues

-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020. -Healthcare, Economic Assistance, Liability, And Schools (HEALS Act), including S. 4317 the Safe to Work Act; S. 4318, the American Workers, Families, And Employers Assistance Act; S. 4321, the Continuing Small Business Recovery And Paycheck Protection Program Act; S. 4322, the Safely Back To School And Back To Work Act; and S. 4323, Time to Rescue United States Trusts Act of 2020 (TRUST Act). -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 8308, to amend the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person, and for other purposes.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301200415.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301177661.xml

Lobbying Issues

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Medicare and Medicaid Programs: Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4190-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -S.2543, The Prescription Drug Pricing Reduction Act of 2019. -Policies that impact public programs payments for high cost drugs including gene therapies.

Agencies Lobbied

Type of Issue

Lobbying Issues

-Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. - Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. - Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, The No Surprises Act; and H.R. 5800, The Ban Surprise Billing Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301126505.xml

Lobbying Issues

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -S.2543, The Prescription Drug Pricing Reduction Act of 2019. -H.R. 2296, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301077540.xml

Lobbying Issues

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -The Prescription Drug Pricing Reduction Act of 2019 (Chairman's Mark). -H.R. 2996, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act. -Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients. -Issues related to utilization management and S.2546, The Safe Step Act of 2019, legislation to amend the Employee Retirement Income Security Act (ERISA) to require group health plans to streamline step therapy protocols and better ensure patients are able to access treatment.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301057925.xml

Lobbying Issues

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301036887.xml

Lobbying Issues

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301016000.xml

Lobbying Issues

Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021. Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P).

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans. 21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q32018 on April 22, 2019 Original Filing: 301036918.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 22, 2018. Original Filing: 300997220.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300977282.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300955292.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to H.R.1625, the Consolidated Appropriations Act of 2018.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 22, 2018. Original Filing: 300936167.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 3545 and Protecting Jessica Grubbs Legacy Act (Legacy Act), S. 1850.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300915829.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300896451.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12017 on July 10, 2017 Original Filing: 300882828.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300875356.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 23, 2017. Original Filing: 300855546.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300838718.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to mental health and general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015. Issues related to S. 1945, the Mental Health Reform Act of 2015, S. 524 the Comprehensive Addiction and Recovery Act of 2016, and S. 2680, the Mental Health Reform Act of 2016; H.R. 5046 the Comprehensive Opioid Abuse Reduction Act and H.R. 2646 the Helping Family in Mental Crisis Act of 2016. Issues relating to employer sponsored healthcare.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300820064.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 12, 2016. Original Filing: 300790218.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 20, 2016. Original Filing: 300782391.xml

Lobbying Issues

Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, including H.R. 2570 and H.R. 2582. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 1600, the Patient's Access to Treatments Act of 2015. Issues relating to H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act, and H.R. 2579 - Securing Care for Seniors Act of 2015. Issues related to the introduction of S. 2104, A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Also, issues related to H.R. 928 and S. 183, Jobs and Premium Protection Act and medicare supplemental insurance. In addition, in support of implementation of expatriate provisions in H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015. Issues relating to the introduction of H.R. 1624 - Protecting Affordable Coverage for Employees Act, H.R. 3462, and S. 775, the Self Insurance Protection Act. Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2015. Original Filing: 300762956.xml

Lobbying Issues

Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, including H.R. 2570 and H.R. 2582. Isues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 1600, the Patient's Access to Treatments Act of 2015. Issues relating to the reintroduction of H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013, and H.R. 2753 - Securing Care for Seniors Act of 2013. Issues related to the instroduction of S. 2104A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.

Agencies Lobbied

Type of Issue

Lobbying Issues

Issues relating to general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Also, issues related to H.R. 928 and S. 183, Jobs and Premium Protection Act and medicare supplemental insurance. In addition, in support of implementation of expatriate provisions in H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015. Issues relating to the introduction of H.R. 1624 - Protecting Affordable Coverage for Employees Act, H.R. 3462, and S. 775, the Self Insurance Protection Act. . Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2015. Original Filing: 300744669.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2015. Original Filing: 300726427.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300706852.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300687660.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 21, 2014. Original Filing: 300669059.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300648352.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 21, 2014. Original Filing: 300625800.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q32013 on Jan. 21, 2014 Original Filing: 300625832.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300605576.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300581764.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 4, 2013. Original Filing: 300547291.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 22, 2013. Original Filing: 300538510.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Registration

3rd Quarter, 2012

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 16, 2012. Original Filing: 300507843.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2012. Original Filing: 300497423.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12012 on July 20, 2012 Original Filing: 300497536.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300471110.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300448180.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 18, 2011. Original Filing: 300418357.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q22011 on Dec. 2, 2011 Original Filing: 300433226.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300402367.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12011 on April 19, 2011 Original Filing: 300369340.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 18, 2011. Original Filing: 300367036.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 19, 2011. Original Filing: 300346608.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q32010 on Jan. 24, 2011 Original Filing: 300355759.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2010. Original Filing: 300323630.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300296014.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2010. Original Filing: 300269439.xml

Lobbying Issues

Issues relating to General Health and Health Care LegislationS. 391/H.R. 1321 -- Healthy Americans Act S. 1753/H.R. 3717/ S. 803/ H,R. 1897 -- Healthy Workforce Act S. 1099/H.R. 2520 - Patient's Choice Act S. 1679 -- "An originial bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce." Medicare Administrative Contracting business America's Healthy Future Act of 2009 ( unnumbered Senate Bill) H.R. 3200 -- America's Affordable Health Choices Act of 2009 H.R. 3962 -- Affordable Health Care for America Act H.R. 3590 -- Patient Protection and Affordable Care Act H.R. 4872 -- Health Care and Education Reconciliation Act of 2010

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q42009 on Jan. 26, 2010 Original Filing: 300249982.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300240684.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 20, 2009. Original Filing: 300216014.xml

Lobbying Issues

See Attached List.S. 391/H.R. 1321 -- Healthy Americans Act. S. 1753/H.R. 3717/S. 803/H.R. 1897 -- Healthy Workforce Act. S. 1099/H.R. 2520 -- Patient's Choice Act. H. Con Res 85/S. Con Res 13 -- setting forth the Congressional budget for the U.S. Government for FY 2010, as it relates to health care reform. Health care reform legislation as it relates to insurance coverage and regulations, including the creation of a new government health insurance program, federal regulation of health insurers and employer sponsored coverage including taxation of employer-provided health benefits and encouraging employment-based wellness programs. S. 1679. Medicare Administrative Contracting business. America's Healthy Future Act of 2009 (unnumbered Senate bill). H.R. 3200-- America's Affordable Health Choices Act of 2009.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 16, 2009. Original Filing: 300180711.xml

Lobbying Issues

See Attached ListS. 391/H.R. 1321 -- Healthy Americans Act S. 1753/H.R. 3717/S. 803/H.R. 1897 -- Healthy Workforce Act S. 1099/H.R. 2520 -- Patient's Choice Act H.Con Res 85/ S. Con Res 13 -- setting forth the Congressional budget for the U.S. Government for FY 2010, as it relates to health care reform. Health care reform legislation as it relates to insurance coverage and regulations, including the creation of a new government health insurance program, federal regulation of health insurers and employer sponsored coverage including taxation of employer-provided health benefits and encouraging employment-based wellness programs. H.R. 3200 -- TRI- Committee Health Reform - House of Representatives Affordable Health Choice Act - U.S. Senate Medicare Administrative Contracting business

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12009 on July 16, 2009 Original Filing: 300179975.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300159550.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12009 on April 20, 2009 Original Filing: 300161090.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, Cigna Corporation had in-house lobbyists. The report was filed on Jan. 15, 2009. Original Filing: 300120323.xml

Lobbying Issues

See attached list.H.R. 1367/H.R. 1424 -- Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulations. H.R. 2406 -- Healthcare Information Technology Enterprise Intergration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers. H.R. 758 -- Breast Cancer Patient Protection Act S.1693 -- Wired for Health Care Quality Act S.1693 -- Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system. S.1224 -- SCHIP Reauthorization S.1408 -- Health Information Technology Act of 2007 S.1455 -- National Health Information Technology and Privacy Advancement Act of 2007 S.334/H.R. 3163/ H.R. 6444 -- Healthy Americans Act S.495 -- Personal Data Privacy and Security Act of 2007 S.628 -- Critical Access to Health Information Technology Act of 2007 H.R. 7129 -- Several Approaches to Reduce the Uninsured Act of 2008

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, Cigna Corporation had in-house lobbyists. The report was filed on Oct. 15, 2008. Original Filing: 300095973.xml

Lobbying Issues

See attached list.H.R. 1367 /H.R.1424--Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulations. H.R. 2406--Healthcare Information Technology Enterprise Integration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers. H.R.758--Breast Cancer Patient Protection Act. S.1693--Wired for Health Care Quality Act. S. 1693--Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system. S. 358--Genetic Information Nondiscrimination Act of 2007. S. 1224--SCHIP Reauthorization. S. 1408--Health Information Technology Act of 2007. S. 1455--National Health Information Technology and Privacy Advancement Act of 2007. S. 334--Healthy Americans Act. S. 495--Personal Data Privacy and Security Act of 2007. S. 628--Critical Access to Health Information Technology Act of 2007.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, Cigna Corporation had in-house lobbyists. The report was filed on July 16, 2008. Original Filing: 300069984.xml

Lobbying Issues

See attached list.S. 334, Healthy Americans Act (Wyden) S.1693, Wired for Health Care Quality Act (Kennedy) H.R. 2406, Healthcare Information Technology Enterprise Integration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers. S. 1693, Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system. H.R. 1367 /H.R.1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulations. S. 558, Mental Health Parity Act, as it pertains to the provisions of mental health benefits. Educate specific Members of Congress on CIGNA bid for a Medicare Administrative contract and any change that will impact providers in their constituencies as a result of being awarded or losing a bid. S. 358/H.R. 493, Genetic Information Nondiscrimination Act of 2007 S. 628, critical Access to Health Information Technology Act of 2007 S. 495, Personal Data Privacy and Security Act of 2007 S. 1455, National Health Information Technology and Privacy Advancement Act of 2007 S. 1408, Health Information Technology Act of 2007 S. 1224, CIPH Reauthorization H.R 6357, To amend the Public Health Services Act to promote the adoption fo health information technology as it pertains to the adoption of a nationawide health infomation system

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Amendment

Cigna Corporation amended a lobbying report for in-house lobbying in Q12008 on Aug. 4, 2008 Original Filing: 300085103.xml

Lobbying Issues

See attached list.S. 334, Healthy Americans Act (Wyden) S.1693, Wired for Health Care Quality Act (Kennedy) H.R. 2406, Healthcare Information Technology Enterprise Integration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers. S. 1693, Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system. H.R. 1367 /H.R.1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulations. S. 558, Mental Health Parity Act, as it pertains to the provisions of mental health benefits. Educate specific Members of Congress on CIGNA bid for a Medicare Administrative contract and any change that will impact providers in their constituencies as a result of being awarded or losing a bid. S. 358/H.R. 493, Genetic Information Nondiscrimination Act of 2007 S. 628, critical Access to Health Information Technology Act of 2007 S. 495, Personal Data Privacy and Security Act of 2007 S. 1455, National Health Information Technology and Privacy Advancement Act of 2007 S. 1408, Health Information Technology Act of 2007 S. 1224, CIPH Reauthorization S. 1022, A bill to eliminate funding shortfalls for SCHIP S. 1023, A bill to eliminate funding shortfalls for SCHIP H.R. 1368, Personalized Health Information Act of 2007 H.R. 1329, Guaranteed Access for SCHIP's Target Population Act of 2007 H.R. 976, Children's Health Insurance Program Reauthorization Act as it pertains to health insurance coverage of children H.R. 3162, CHAMP Act, as it pertains to coverage of children, payments to Medicare Advantage plans, and other spending offsets H.R. 2764, the Department of State, Foreign Operations & Related Programs Appropriation bills, as it realtes to SCHIP fudning, payments to Medicare Advantage Plans, and other spending offsets.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, Cigna Corporation had in-house lobbyists. The report was filed on April 21, 2008. Original Filing: 300049136.xml

Lobbying Issues

See attached list.S. 334, Healthy Americans Act (Wyden) S.1693, Wired for Health Care Quality Act (Kennedy) H.R. 2406, Healthcare Information Technology Enterprise Integration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers. S. 1693, Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system. H.R. 1367 /H.R.1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulations. S. 558, Mental Health Parity Act, as it pertains to the provisions of mental health benefits. Educate specific Members of Congress on CIGNA bid for a Medicare Administrative contract and any change that will impact providers in their constituencies as a result of being awarded or losing a bid. S. 358/H.R. 493, Genetic Information Nondiscrimination Act of 2007 S. 628, critical Access to Health Information Technology Act of 2007 S. 495, Personal Data Privacy and Security Act of 2007 S. 1455, National Health Information Technology and Privacy Advancement Act of 2007 S. 1408, Health Information Technology Act of 2007 S. 1224, CIPH Reauthorization S. 1022, A bill to eliminate funding shortfalls for SCHIP S. 1023, A bill to eliminate funding shortfalls for SCHIP H.R. 1368, Personalized Health Information Act of 2007 H.R. 1329, Guaranteed Access for SCHIP's Target Population Act of 2007 H.R. 976, Children's Health Insurance Program Reauthorization Act as it pertains to health insurance coverage of children H.R. 3162, CHAMP Act, as it pertains to coverage of children, payments to Medicare Advantage plans, and other spending offsets H.R. 2764, the Department of State, Foreign Operations & Related Programs Appropriation bills, as it realtes to SCHIP fudning, payments to Medicare Advantage Plans, and other spending offsets.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed